Drug Trial Radar · NCT00200343
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
596
Actual
Start
Jul 2002
Primary completion
Not stated
Study completion Dec 2004
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan. The primary objectives of this study are to verify the superiority of efficacy of UDCA 600 or 900mg/day to that of 150mg/day and the safety of UDCA treatment.
Conditions
- Chronic Hepatitis C
Interventions
Ursodeoxycholic acid 150mg / dayDrug
Ursodeoxycholic acid, 150mg/ day, three times a day at meals
Ursodeoxycholic acid 600mg / dayDrug
Ursodeoxycholic acid, 600mg/ day, three times a day at meals
Ursodeoxycholic acid 900mg / dayDrug
Ursodeoxycholic acid, 900mg/ day, three times a day at meals
Primary outcomes
What the sponsor says the trial is designed to measure.
- Alanine Aminotransferase at BaselineTime frame: 0 week
- Percentage Change of Alanine Aminotransferase From Baseline at Week 24Time frame: 24 weeks (from baseline to Week 24)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Gastroenterology, University of Tokyo
Hongo, Bunkyo-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.